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Haemophilus ducreyi, the causative agent of chancroid, is highly resistant to the complement-mediated
bactericidal activity of normal human serum (NHS). Previously, we identified DsrA (for ducreyi serum
resistance A), a major factor required for expression of the serum resistance phenotype in H. ducreyi. We
describe here a second outer membrane protein, DltA (for ducreyi lectin A), which also contributes to serum
resistance in H. ducreyi. Isogenic dltA mutants, constructed in 35000HP wild-type and FX517 dsrA backgrounds,
were more susceptible to the bactericidal effects of NHS than each respective parent, demonstrating the
additive effect of the mutations. Furthermore, expression of dltA in H. influenzae strain Rd rendered this highly
susceptible strain partially resistant to 5% NHS compared to a vector-control strain. Although primary basic
local alignment search tool analysis of the dltA open reading frame revealed no close bacterial homologue,
similarity to the -chain of the eukaryotic lectin ricin was noted. DltA shares highly conserved structural
motifs with the ricin  chain, such as cysteines and lectin-binding domains. To determine whether dltA was a
lectin, ligand blots and affinity chromatography experiments were performed. DltA was affinity purified on
immobilized lactose and N-acetylgalactosamine, and N-glycosylated but not glycosidase-treated model glyco-
proteins bound DltA. These data indicate that DltA is a lectin with specificity for lactose-related carbohydrates
(CHO) and is important for H. ducreyi serum resistance.
Chancroid is a sexually transmitted genital ulcer disease (re-
viewed in references 34, 39, 65, and 75) characterized by pain-
ful ulcers and suppurative lymphadenopathy. Although rare
in the United States (www.cdc.gov/std/stats00/slides/otherstds
/sld002.htm) and Canada (http://cythera.ic.gc.ca/dsol/ndis
/disease2/chane.html), chancroid is common in developing,
resource-poor countries worldwide (65). Interest in the study
of chancroid pathogenesis has been renewed since the discov-
ery that genital ulcer diseases, including chancroid, are impor-
tant independent cofactors in the heterosexual transmission of
the human immunodeficiency virus (7, 9, 29, 40, 50). In fact,
chancroid incidence is highest in countries where human im-
munodeficiency virus is epidemic (68).
Chancroid is caused by the gram-negative pleomorphic bac-
terium Haemophilus ducreyi (reviewed in reference 1). This
fastidious microorganism is a strict human pathogen that lo-
calizes to the genital epithelia and does not cause systemic
infection (39, 65, 75). Although H. ducreyi was first identified
by Auguste Ducrey in 1889, the mechanisms responsible for
the pathogenesis of chancroid remain poorly understood.
Several microorganisms, including H. ducreyi, can survive in
the presence of fresh normal human serum (NHS), which
contains immunoglobulins and complement (C). C is a com-
plex system of proteins that promotes killing of pathogens by
opsonophagocytosis and lysis (38, 57), among other functions.
Capsules of both gram-positive and gram-negative bacteria
(12, 57), the O antigen on lipopolysaccharides of gram-nega-
tive bacteria (57), sialic acids on lipooligosaccharides (LOS)
(54, 57), and several membrane proteins in a variety of bacte-
rial species (16, 54, 57) have been shown to be involved in
providing protection from the activity of C. These bacterial
components affect C activity by a variety of ways, such as
spatially hindering the binding of C proteins (49) or antibod-
ies (15) to the bacterial membrane, by binding “blocking”
antibodies (58), by facilitating the inactivation of the C cas-
cade through the binding of negative regulators of C (2, 37, 52,
53, 55, 56), by preventing the productive insertion of the mem-
brane attack complex into the outer membrane (OM) (24, 30),
or by interfering with opsonophagocytosis (71).
Numerous studies have documented the serum resistance of
H. ducreyi (16, 19, 25, 33, 41–43). Since H. ducreyi is unencap-
sulated, the serum resistance phenotype is not due to the
presence of a capsule (65). Furthermore, the ability to sialy-
lated LOS does not render H. ducreyi strains resistant to NHS
(25). Surprisingly, isogenic mutants of 35000HP lacking the
DD-heptose and all subsequent terminal lactose-related carbo-
hydrates (CHO) remain fully resistant to NHS (25). However,
mutations affecting the ability to express the 30-kDa OM pro-
tein (OMP) DsrA substantially affect serum resistance (16),
although minor effects were also seen in mutants lacking the
major OMP (MOMP) (25). Earlier reports by Odumeru et al.,
who used nonisogenic strains expressing truncated LOS (41,
42) and containing cryptic mutations in dsrA, suggested that
LOS composition might affect serum susceptibility in H. du-
creyi. However, expression of dsrA restored serum resistance in
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these serum-susceptible strains without affecting LOS electro-
phoretic mobility (16).
Lectins are CHO-binding proteins found ubiquitously in na-
ture, in eukaryotes and prokaryotes, and from single-cell to
multicellular organisms (10). Lectins bind CHO through hy-
drophobic interactions (31) and can be grouped according to
their CHO-recognition domains (CRD) (10). The lectin ricin,
whose  chain binds terminal galactose and GalNAc residues,
is an R-type (ricin-like) lectin. R-type CRDs are the only types
of CRDs found in bacterial lectins (10). Lectins are important
in cell adhesion and recognition because they bind CHO rap-
idly and in a reversible fashion (62). Twenty-five years ago,
Ofek et al. showed that surface-exposed bacterial lectins were
required for initiation of infection (44). Since then, several
bacterial lectins have been shown to be involved in the attach-
ment of host cell glycoconjugates, such as the P pili and type 1
fimbriae of Escherichia coli (78), the filamentous hemaggluti-
nin of Bordetella pertussis (63), several adhesins of nontypeable
Haemophilus influenzae (70), and type IV pili of Pseudomonas
aeruginosa (20).
Thus far, no lectin has been identified or shown to be in-
volved in the pathogenesis of chancroid. We demonstrate here
that DltA is a lectin involved in the serum resistance of H.
ducreyi.
(Portions of this study were presented at the 7th Interna-
tional Symposium on Haemophilus ducreyi Pathogenesis and
Chancroid in June 2003 in Ottawa, Ontario, Canada.)
MATERIALS AND METHODS
Strains and media. Strains used in the present study are described in Table 1.
H. ducreyi strains were routinely maintained by subculture in 5% CO2 at 34.5°C
on chocolate agar plates (CAP) containing 1 GGC (0.1% glucose, 0.01%
glutamine, 0.026% cysteine) (74) and 5% fetal bovine serum (FBS) (Sigma, St.
Louis, Mo.). For broth cultures, H. ducreyi was grown in GC broth (Difco,
Detroit, Mich.) containing 5% FBS and 1% IsoVitalex (BBL, Cockeysville, Md.)
at 34.5°C with 5% CO2.
E. coli strains were grown either on Luria-Bertani (LB) agar or in LB broth.
H. influenzae strains were grown on CAP supplemented with 1% IsoVitalex. The
following concentrations of antibiotics were used: 100 g of ampicillin (Amp)/ml,
30 g of chloramphenicol (Cm)/ml, 30 g of kanamycin (Kan)/ml, and 100 g of
streptomycin (Sm)/ml.
DIG labeling of FN, Tf, fH, and BSA. Proteins were labeled by using digoxi-
genin-3-0-succinyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (DIG-NHS)
according to the manufacturer’s instructions (Roche Diagnostics GmbH, Mann-
heim, Germany). Briefly, 1 mg of fibronectin (FN; kindly supplied by Kenneth
Ingram, American Red Cross), 500 g of transferrin (Tf; Sigma, St-Louis, MO)
and factor H (fH; Advanced Research Technologies, San Diego, Calif.), and 1
mg of bovine serum albumin (BSA; Sigma) were exchanged in phosphate-buff-
ered saline (PBS) by using a Centricon 50 concentrator, and then 10.6 l of
DIG-NHS (20 mg/ml in dimethyl sulfoxide [DMSO]) was added to the proteins,
followed by incubation at room temperature for 2 h with gentle mixing. The
reaction was quenched with 100 l of 1 M Tris (pH. 8.0). DIG-labeled proteins
were dialyzed overnight against PBS (pH 8.0) at 4°C to remove any unbound
DIG. The activity of the probes was assessed by titration in a ligand blot as
described below.
Ligand blots with DIG-labeled proteins. Proteins from H. ducreyi cell pellets
(107 CFU/lane) were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (32) under nonreducing and reducing conditions
(as indicated) and transferred to a 0.45-m-pore-size nitrocellulose membrane
by using a Mini-Protean II transfer apparatus (Bio-Rad, Hercules, Calif.). Mem-
branes were blocked for a minimum of 1.5 h in 0.5% Tween 20 in PBS (block),
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype and/or phenotype Source or reference
Strains
H. ducreyi
35000HPa Human-passaged variant of strain 35000 (21) S. M. Spinola et al. (67)
FX517 35000HPdsrA::CATc 16
FX533 35000HPdltA::Kan This study
FX534 35000HPdsrA::CAT dltA::Kan This study
H. influenzae
Rd Wild type ATCCb
Rd/p1286 Strain Rd containing pUNCH1286 This study
Rd/pLSKS Strain Rd containing pLSKS This study
E. coli
DH5 recA gyrB Bethesda Research Labs
BL21(DE3)/pLYSs Cmr Invitrogen
Plasmids
pCR2.1-TOPO PCR cloning vector; Kanr Ampr Invitrogen
pCRT7/NT-TOPO Expression vector; Ampr Invitrogen
pLSKS H. ducreyi shuttle vector; Smr 77
pRSM1791 Mutagenesis plasmid; -Gal Ampr 5
pUNCH1284 dltA expression clone in pCRT7/NT-TOPO; used for rDltA purification This study
pUNCH1285 dltA PCR clone in pCR2.1-TOPO This study
pUNCH1286 dltA subclone in pLSKS This study
pUNCH1287 Mutagenized dltA; pUNCH1286 mutagenized with Kan cassette in pLSKS; Kanr Smr This study
pUNCH1289 Mutagenized dltA subclone in pRSM1791 This study
pUNCH1295 NcaA expression clone This study
a 35000HP was isolated from a pustular lesion of a human volunteer 13 days after inoculation.
b ATCC, American Type Culture Collection.
c CAT, chloramphenicol acetyltransferase.
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incubated at room temperature for 1 h with DIG-labeled proteins (1 g/ml in
block), and washed three times in 0.05% Tween 20 in PBS. Membranes were
thereafter incubated with anti-DIG alkaline phosphatase (anti-DIG-AP) anti-
body (Roche, Indianapolis, Ind.) (1:5,000 in block) for 1 h at room temperature
and then washed, and detection was performed with a Lumi-Phos WB chemilu-
minescence substrate (Pierce, Rockford, Ill.).
Sequencing DltA and preliminary identification of dltA in the H. ducreyi
genome. Because N-terminal Edman degradation failed twice, we performed in
situ trypsin digestion and mass spectrometry (MS) to sequence DltA. Sarkosyl-
insoluble (SI) OM preparations were subjected to preparative SDS-PAGE and
Coomassie blue staining, and the putative DltA band was cut out. To verify that
we had extracted the correct band from the gel, part of the gel slice submitted for
trypsin studies was electroeluted. The eluted protein, but not a control protein
migrating just above DltA, bound FN in a ligand blot (data not shown). Internal
tryptic peptide mapping of the gel slice was done, followed by matrix-assisted
laser desorption ionization–time-of-flight MS, and MS/MS data were generated
at the UNC Microchemical Core. We used the resulting protein sequence to
search the H. ducreyi genome databases (www.stdgen.lanl.gov/ or www.ncbi.nlm
.nih.gov/genomes/chrom.cgi?gi  309&db  G). The databases kindly supplied
by Robert Munson (Ohio State University).
Globomycin treatment of H. ducreyi. A 20-ml liquid culture of H. ducreyi
inoculated with 2.4  106 CFU/ml was allowed to grow for 4 h at 34.5°C with 5%
CO2. At that point, the culture was split into two 10-ml cultures. Globomycin
(final concentration, 15 g/ml) was added to one culture, and DMSO alone
(1.5%) was added to the other (negative control). At 4 h after the addition of
DMSO or globomycin, 1 ml of the culture (optical density at 600 nm [OD600] of
0.2 [108 CFU]) was harvested and then pelleted, and the cells were resus-
pended in 100 l of Laemmli sample buffer with 2-mercaptoethanol (ME)
(i.e., reducing conditions). The samples (10 l) were thereafter subjected to
SDS-PAGE and Western blotting with anti-recombinant DltA (anti-rDltA), anti-
DsrA, and anti-Hlp antibodies.
Cloning and mutagenesis of the dltA gene. The dltA gene was amplified by
PCR from whole cells of H. ducreyi strain 35000HP as the template and oligo-
nucleotides DLTA.01 (5-CGC TTG TAC AAG CGG GC-3) and DLTA.02
(5-CAG CTT ACA AAA TGA TGG GC-3) as primers. These oligonucleotides
were based on the H. ducreyi genome sequence and flank the dltA open reading
frame (ORF). An 815-bp product was predicted from PCR. The conditions for
PCR were as follows: a single denaturing step was performed for 5 min at 95°C,
followed by 35 cycles of denaturation for 1 min at 95°C, annealing at 50°C for 1
min, and elongation at 72°C for 1 min. A single product of 800 bp was observed
and was gel purified by using the Qiagen PCR purification kit (Valencia, Calif.).
The PCR product was cloned into the pCR2.1-TOPO according to the manu-
facturer’s instructions to form pUNCH1285. To create a plasmid for comple-
mentation of dltA mutants, pUNCH1286 was constructed. The insert in
pUNCH1285 was digested with EcoRI, Klenow treated, and gel purified. The
vector pLSKS was digested with EcoRV and ligated to the insert containing dltA
from pUNCH1285 to form pUNCH1286. The dltA ORF in pUNCH1286 was
mutagenized by insertion of a Kan cassette. pUNCH1286 was made linear by
digestion with Eco47III and ligated to EcoRI- and Klenow-treated Kan cassette
from pUC4K to form pUNCH1287. The mutagenized dltA was then moved into
suicide vector pRSM1791 (5) by digesting pUNCH1287 with XbaI and KpnI and
filling the overhangs with the T4 DNA polymerase and deoxynucleoside triphos-
phates. Plasmid pRSM1791 was digested with NotI, treated with Klenow, and
ligated to the mutagenized dltA insert from pUNCH1287 to create pUNCH1289.
pUNCH1289 was electroporated into H. ducreyi 35000HP, and transformants
were isolated on CAP containing Kan. Kan-resistant transformants (putative
cointegrates) were streaked onto Kan–X-Gal (5-bromo-4-chloro-3-indolyl--D-
galactopyranoside) CAP to isolate mutants that had lost the wild-type locus (5).
Mutants were confirmed by PCR amplification with whole cells of the mutants as
DNA template and the oligonucleotides DLTA.01 and DLTA.02 as primers
under the conditions described above. As expected, a 2-kb band was amplified in
the mutants (data not shown).
Complementation of dltA mutants (FX533 and FX534) and expression of dltA
in H. influenzae. Plasmid pUNCH1286dltA was introduced into H. ducreyi strains
FX533 and FX534 (Table 1) and in H. influenzae strain Rd by electroporation.
Expression of dltA from pUNCH1286 was assessed by Western and DIG-FN
ligand blots (Fig. 4).
Cloning, expression, and purification of rDltA. The dltA gene was amplified
from 35000HP whole cells by using oligonucleotides DLTA.03 (5-TGT GTA
TAT GCA CCT CCC G-3) and DLTA.02. The PCR product was ligated to
pCRT7/NT-TOPO to form pUNCH1284 and transformed into E. coli BL21
(DE3)/pLysS (Invitrogen, Carlsbad, Calif.). This construct eliminated the puta-
tive lipoprotein N-terminal signal sequence and replaced it with an N-terminal
fusion tag. After induction, the transformants were examined by SDS-PAGE and
Coomassie blue staining for the presence of an abundant novel protein compared
to the vector control. We observed several clones that contained an 30-kDa
protein that bound DIG-FN in ligand blots. One clone was chosen for further
study and designated pUNCH1284 (Table 1). The insert from pUNCH1284 was
sequenced on both strands at the University of North Carolina at Chapel Hill
Sequencing Facility utilizing Taq terminator chemistry.
Using the method of Qi et al. (51), rDltA was purified as previously described
(17, 73). Inclusion bodies containing the recombinant proteins were subsequently
purified by four centrifugations (10,000  g for 20 min). Using SDS-PAGE and
Coomassie blue staining, it was determined that rDltA was 	95% pure (data not
shown).
Generation of anti-DltA antisera. Elite New Zealand White rabbits were
immunized four times, at 2-week intervals, with 200 g of rDltA in complete
Freund adjuvant for the first immunization and in incomplete Freund adjuvant
for the last three immunizations at Covance Research Products, Inc. (Denver,
Pa.). Eight weeks after the first immunization, rabbits were exsanguinated, and
sera were collected and stored at 
70°C for later use.
Affinity chromatography of DltA with immobilized CHO. Whole H. ducreyi
cells (ca. 5  108 CFU) were solubilized in 2% Zwittergent 3,14 in Tris-EDTA-
NaCl buffer for 1 h at room temperature and centrifuged for 20 min at 10,000 
g, and the pellet was discarded. A total of 900 l of the supernatant was mixed
with 100 l of a 50% slurry of acrylamide-bound CHO (EY Laboratories, Inc.,
San Mateo, Calif.), followed by incubation at room temperature for 2 h. The
pellet was washed four times, with a changing of the tubes between washes 3 and
4, and then 100 l of 1 Laemmli buffer was added to the final pellet. Then, 20
l of this suspension was subjected to SDS-PAGE and a ligand blot with
DIG-FN (0.5 g/ml) and anti-rDltA (1:30,000).
PNGase F treatment of DIG-labeled probes. Deglycosylation of DIG-labeled
probes with N-glycosidase F (PNGase F) was performed according to the man-
ufacturer’s instructions (New England Biolabs, Beverly, Mass.) as follows. DIG-
labeled probes were boiled 10 min in denaturing buffer (5% SDS and 10% ME;
New England Biolabs) and then incubated 1 h at 37°C in 1 G7 buffer (0.05 M
sodium phosphate [pH 7.5]), 1% NP-40, and 250 U of PNGase F. Controls
containing no PNGase F (
) were treated concurrently. Since boiling affected
the integrity of DIG-fH, this probe was not subjected to denaturation prior to its
treatment with PNGase F.
Fractionation of DltA. OMs from H. ducreyi (grown in 1.5 liter of Columbia
broth [Difco, Sparks, Md.] supplemented with 1% GGC and 1.5% FBS) were
prepared as previously described (13), with several modifications. Whole H. du-
creyi cells were passed through a French press and centrifuged at 10,000  g at
4°C. The supernatant was further centrifuged at 100,000  g for 1 h at 4°C. The
pellet was rinsed three times with 10 mM HEPES and then solubilized in 1%
N-lauroylsarcosine (Sarkosyl) in 10 mM HEPES (pH 8.0) for 30 min at 37°C. The
suspension was then subjected to another 1 h of centrifugation at 100,000  g.
The SI pellet was resuspended in sterile PBS and stored at 
20°C. Protein
content was determined by using the BCA protein assay kit (Pierce), and 10 g
of each fraction was subjected to SDS-PAGE and Western blotting.
Protease cleavage of surface proteins of H. ducreyi. Liquid media were inoc-
ulated with 2.4  106 CFU of H. ducreyi strains FX517 and FX533/ml. After 9 h
of growth, the bacterial cells were harvested, washed three times in PBS plus
Ca/Mg, and resuspended to an OD600 of 0.4 (ca. 2  108 CFU/ml). A 1-ml
sample of the bacterial suspension from both strains was subjected to centrifu-
gation, and the pellet was suspended in Laemmli sample buffer and labeled as
“time zero.” To a 2.5-ml sample of bacterial suspension of both strains was added
12.5 l of chymotrypsin at 1 mg/ml (final concentration, 5 g/ml) or 5 l of
trypsin at 10 mg/ml (final concentration, 20 g/ml). The suspensions were incu-
bated at 35°C for 2 min and then centrifuged, and the pellets were resuspended
in Laemmli buffer. The samples were subjected to SDS-PAGE and Western
blotting with anti-rDltA, anti-rDsrA, anti-Hlp and anti-rHgbA antibodies. For
simplicity sake, we only show protease cleavage of strain FX517 (positive control
for cleavage) because we have evidence that DsrA shields some antigens on the
surface of H. ducreyi (data not shown). Thus, DltA would more accessible to
protease activity in the absence of DsrA. Protease cleavage in strain 35000HP is
identical to that of FX517 (data not shown).
Surface iodination of whole H. ducreyi. H. ducreyi strains 35000HP, FX517,
FX533, and FX534 at an OD600 of 1.0 (ca. 5  108 CFU) were prepared. The
cells were washed once and resuspended in PBS plus Ca/Mg. First, 1 mCi of
[125I]Na was preactivated in Iodo-Gen tubes (Pierce), and then 0.25 mCi was
added to each of the bacterial suspensions. The iodination process was allowed
to proceed for 2 min to prevent lysis of bacteria and iodination of cytoplasmic
proteins. The iodination reaction was quenched by adding cold GCB. The cells
were washed three times with cold GCB, and the final pellet was suspended in
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Laemmli sample buffer plus ME. A sample containing 60,000 cpm was sub-
jected to SDS-PAGE and Coomassie blue staining. The gel was dried before
overnight exposure to 
70°C with intensifying screens.
Bactericidal assay. The resistance of H. ducreyi to NHS was determined as
previously described (16). Briefly, bacteria (200 CFU) and NHS, the source of
complement (5, 10, or 50%), were incubated for 45 min at 34.5°C in 5% CO2.
Aliquots were plated onto CAP, and colonies were counted after incubation at
34.5°C in 5% CO2 for 48 h.
Analysis of LOS. Whole cells from H. ducreyi (ca. 2  108 CFU) were sus-
pended in Laemmli sample buffer (10% glycerol, 5% ME, SDS, 0.0025%
bromophenol blue) and incubated with proteinase K (50 g/ml final concentra-
tion) for 1 h at 56°C (27), boiled for 1 min, and stored at 4°C. Approximately 5 l
of this preparation was subjected to SDS-PAGE and silver stained according to
the method of Tsai and Frasch (76) or subjected to Western blotting with
monoclonal antibody 3E6 that reacts with purified LOS from H. ducreyi strain
35000HP (22, 69).
Statistical analysis. Data from the bactericidal assays were compared with a
paired t test by using the Excel (Microsoft) software. A P value of 0.05 was
accepted as the level of statistical significance.
Nucleotide sequence. The dltA gene corresponds to ORF Hd0746 of the
H. ducreyi genome sequence (www.stdgen.lanl.gov/). The sequence of the H. du-
creyi genome was released under GenBank accession no. AE017143.
RESULTS
DltA is a 22-kDa H. ducreyi protein that binds FN. We have
previously shown that DsrA binds keratinocytes and the extra-
cellular matrix (ECM) protein vitronectin (8). In order to
better understand ECM protein binding by H. ducreyi, we de-
veloped a ligand blot assay using DIG-labeled ECM proteins,
including FN. We observed a 22-kDa low-abundance (by Coo-
massie blue staining) H. ducreyi protein that bound FN and
that was expressed by all seven H. ducreyi strains tested (Fig.
1A and Table 2). Based on the functional characterization
described below, this protein was named DltA (for ducreyi
lectin A).
To determine whether DltA could form multimers such as
DsrA and whether it contained intradisulfide bonds, we incu-
bated whole cells of H. ducreyi strain 35000HP at 37 and 100°C
in nonreducing (
ME) and reducing (ME) conditions.
DIG-FN bound much better to DltA in nonreducing condi-
tions (Fig. 1B3). Furthermore, DltA does not appear to form
multimers (Fig. 1B4), as is the case for DsrA (Fig. 1B5).
DNA sequence and deduced amino acid sequence of the H.
ducreyi 22-kDa FN-binding DltA protein from strain 35000HP.
DltA was subjected to trypsin digestion and MS as described in
Materials and Methods. The protein sequence data were used
to search the H. ducreyi genome and matched to a 540-bp ORF
(H. ducreyi genome Hd0746). The GC content of this ORF
(42%) was comparable to the overall GC content of this
organism (38 to 39 mol%) (1). There were no obvious 
35
(TGATAA) or 
10 (TATATT) E. coli consensus sequences
FIG. 1. Identification of a novel 22-kDa H. ducreyi protein that
binds FN. (A) Solubilized proteins from H. ducreyi (Table 2) (ca. 107
CFU/lane) were subjected to SDS-PAGE (reducing conditions) and
ligand blotting with DIG-FN as a primary probe and anti-DIG-AP as
a secondary probe and developed by using chemiluminescence. Panel
1 of this figure shows the Ponceau S stain of the membrane prior to the
ligand blot shown on panel 2. (B) Proteins from H. ducreyi (107
CFU/lane) were solubilized at either 37 or 100°C, subjected to SDS-
PAGE in reducing (BME [left side]) and nonreducing conditions
(
BME [right side]) and Western-ligand blotting with DIG-FN (panel
3), anti-rDltA (panel 4), or anti-rDsrA (panel 5) as primary probes and
anti-DIG-AP or anti-rabbit-AP as secondary probes. Blots were de-
veloped by using chemiluminescence.









CIPA75 HMC32 Pasteur Institute 1952 P. Totten (11)
CIPA77 HMC104 Pasteur Institute 1952 P. Totten (11)
CIP542 Canada France 1954 W. Albritton
CHIA HMC1 CDCa 1953 P. Totten (11)
M90-02 HMC48 Bahamas 1995 P. Totten (11)
406 HMC49 Jackson, Miss. 1995 P. Totten (11)
a CDC, Centers for Disease Control and Prevention.
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identified upstream of this ORF. The gene upstream of dltA,
Hd0747 (nhaA), is in the same orientation as dltA and encodes
a putative Na/H antiporter. Downstream of the dltA ORF
and in the opposite orientation is Hd0745, a gene encoding a
protein of unknown function.
The nucleotide sequence of the dltA ORF predicts an im-
mature lipoprotein of 21,016 Da containing 179 amino acids
(Fig. 2). Cleavage of DltA at its putative signal peptidase II
cleavage site would yield a mature protein of 164 amino acids.
With the addition of a lipid component, this would be consis-
tent with its electrophoretic mobility at 22 kDa, determined by
ligand blotting (Fig. 1). DltA contains seven cysteines (Fig. 2),
and the mature protein is predicted to have a pI of 8.30 (DNA
STRIDER).
A BLASTP search performed on the deduced amino se-
quence of full-length DltA revealed no significant similarities
to any known protein. However, sections of DltA had similarity
to various domains of a lipoprotein from Salmonella species, to
xylanases and xylan-binding domains of proteins from Strepto-
myces species, and to parts of an N-acetylgalactosaminyltrans-
ferase from Homo sapiens (data not shown). In addition, pu-
tative conserved domains were found between DltA and the 
chain of ricin, a well-studied R-type lectin, suggesting that
DltA might be a lectin (Fig. 2). DltA shares three imperfect
QRW lectin repeats with the ricin  chain, and the relative
positions of 6 cysteines are conserved in both proteins (Fig. 2).
Taken together, these results suggested that the FN-binding
protein DltA identified above might be a lectin.
Globomycin treatment of H. ducreyi. The data presented
above suggest that DltA is a lipoprotein. To confirm this, we
submitted the signal sequence of DltA to DOLOP (the Data-
base of Bacterial Lipoproteins [http://www.mrc-lmb.cam.ac.uk
/genomes/dolop/]), a website that predicts if a leader sequence
is that of a lipoprotein. It revealed that DltA was a probable
lipoprotein and that its lipobox was the sequence LSGC (un-
derlined in Fig. 2). To further clarify this issue, whole cells of
H. ducreyi were treated with globomycin, a known inhibitor of
signal peptidase II, and subjected to SDS-PAGE and Western
blotting with anti-rDtlA. Globomycin-treated H. ducreyi had an
extra band above DltA that corresponded to the unprocessed
precursor containing the signal sequence (Fig. 3). This phe-
nomenon was also seen in Hlp, a surface-exposed lipoprotein of
H. ducreyi, and was absent in DsrA, which is not a lipoprotein
(Fig. 3). We therefore concluded that DltA is a lipoprotein.
Construction and characterization of H. ducreyi dltA mutant
and dltA dsrA double mutant. Mutants FX533 and FX534 lack-
ing DltA were constructed in 35000HP wild-type and FX517dsrA
backgrounds, respectively. Mutagenesis of the dltA locus in
both strains was confirmed by PCR and Western blot analyses
(data not shown). In PCR, products of 800 bp were amplified
from the parent strains by using primers DLTA.01 and
DLTA.02, a finding consistent with the DNA sequence. In
contrast, 2-kb products were amplified from dltA mutant tem-
plates, a finding consistent with the insertion of the Kan cas-
sette within the dltA locus.
In Western and FN-ligand blot analyses, both FX533
(35000HPdltA) and FX534 (FX517dsrAdltA) failed to express
DltA (Fig. 4). DltA antibody binding and FN binding was
restored in both mutants when DltA was expressed in trans
from pUNCH1286 (Fig. 4) but not from a vector control.
FIG. 2. Predicted amino acid sequence of DltA and alignment of DltA with the ricin  chain. The putative signal peptidase II site, LSGC, is
underlined. The arrow indicates the possible cleavage site. DltA contains seven cysteines shown in reverse highlight. The QXW “lectin repeats”
patterns are indicated in boldface. Only the first module of the ricin  chain is shown. Identity of amino acid is shown by a dark gray highlight,
and a light gray highlight indicates similarity.
FIG. 3. Globomycin treatment of H. ducreyi. H. ducreyi cells were
allowed to grow for 4 h before the addition of globomycin and DMSO.
Four hours later, the cells were pelleted, solubilized in Laemmli sam-
ple buffer, and subjected to SDS-PAGE in reducing conditions (107
CFU/lane) and Western blotting with anti-rDltA, anti-Hlp, and anti-
rDsrA antibodies. Lanes: , addition of globomycin-DMSO in the
culture; 
, addition of DMSO to the culture. Note the additional band
in globomycin-treated culture for DltA and Hlp.
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Furthermore, introduction of pUNCH1286dltA into the heter-
ologous host H. influenzae strain Rd resulted in dltA expres-
sion, as indicated by DltA antibody and DIG-FN binding.
To examine the effect of the dltA mutation on the expression
of other proteins, we subjected OMPs of both parents and
mutants to SDS-PAGE and compared Coomassie-stained
bands. The electrophoretic patterns of OMPs from strains
FX533 and FX534 were indistinguishable from those of their
parents (data not shown). We also examined the effect of the
dltA mutation on LOS expression by SDS-PAGE and silver
staining. No differences were observed. A Western blot probed
with anti-LOS monoclonal antibody 3E6 (22, 69) revealed that
there were no major differences in reactivity between the LOS
moieties of parent and mutant strains (data not shown). There
were also no differences in growth in rich broth between parent
(35000HP and FX517) and mutant (FX533 and FX534) strains
(data not shown).
Determination of the function of DltA. Similarities in the
deduced amino acid sequence between DltA and the ricin 
chain (Fig. 2 and text) suggested that DltA might be a lectin.
To test this hypothesis, we examined the ability of DltA to bind
to immobilized CHO and glycoproteins (Fig. 5). DltA was only
recovered from the lactose and GalNAc affinity columns (Fig.
5). These data were confirmed in a similar affinity chromatog-
raphy experiment with iodinated whole H. ducreyi cells and
immobilized CHO. DltA was enriched, compared to other
OMPs, only when mixed with immobilized lactose or GalNAc
(data not shown).
Additional evidence that DltA is a lectin was obtained from
deglycosylation experiments (36). DIG-labeled glycoproteins
(FN, Tf, and fH) that bound DltA in preliminary experiments
were deglycosylated with PNGase F, which removes N-linked
CHO by cleaving the entire glycose moiety at the first residue
(36, 72). The deglycosylation state of glycoproteins was mon-
itored by Western blots with an AP-conjugated anti-DIG an-
tibody (Fig. 6A). Increased electrophoretic mobility of a probe
was interpreted as removal of the CHO moiety (Fig. 6A).
DIG-fH was efficiently deglycosylated in nondenaturing con-
FIG. 4. Characterization of DltA expression in mutants. Proteins
from solubilized H. ducreyi (107 CFU/lane) were subjected to SDS-
PAGE under nonreducing conditions and Western blotting with anti-
rDltA (panel 1) and DIG-FN (panel 2). Lanes: 35000HP, H. ducreyi
35000HP parental strain; FX533dltA, 35000HP dltA::Kan; FX533
p1286, FX533 complemented in trans with pUNCH1286dltA; FX533
pLSKS, FX533 complemented in trans with the empty vector pLSKS;
FX517dsrA, 35000HP dsrA::CAT; FX534dsrAdltA, 35000HP dltA::
Kan dsrA::CAT; FX534p1286, FX534 complemented in trans with
pUNCH1286dltA; FX534pLSKS, FX534 complemented in trans with
the empty vector pLSKS; H. flup1286, H. influenzae strain Rd con-
taining pUNCH1286dltA; H. flupLSKS, H. influenzae strain Rd con-
taining pLSKS.
FIG. 5. DltA binding to immobilized CHO. Zwittergent 3,14-solu-
ble total H. ducreyi proteins from 109 CFU were mixed with and
allowed to bind to acrylamide beads containing the indicated co-
valently bound CHO or glycoprotein. After the unbound components
were removed, the pellet was solubilized in Laemmli sample buffer and
then subjected to SDS-PAGE under nonreducing conditions and
Western blotting with anti-rDltA (panel 1) or DIG-FN (panel 2).
Lanes: 35000HP-WC(), Zwittergent 3,14-solubilized proteins from
whole H. ducreyi cells (107 CFU/lane) used as positive control; GAL-
NAC, N-acetylgalactosamine; GLCNAC, N-acetylglucosamine; BSM,
bovine submaxillary mucin.
FIG. 6. Effect of PNGase F treatment of DIG-labeled glycopro-
teins on DltA binding. (A) Before (
) and after () treatment with
glycosidase (PNGase F), each DIG-labeled glycoprotein was subjected
to SDS-PAGE under nonreducing conditions and Western blotting
with an anti-DIG probe to determine the effect of PNGase F treatment
on the electrophoretic mobility of the glycoproteins. Deglycosylation
was carried out under denaturing conditions for all probes, except for
DIG-FH. (B) Untreated (
) and PNGase F-treated () DIG-labeled
glycoproteins were tested for their ability to bind DltA in ligand blots
of whole-cell preparations of strain 35000HP (nonreducing conditions).
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ditions (Fig. 6A), but Tf and FN required denaturing condi-
tions to be completely deglycosylated. BSA was not affected by
glycosidase treatment, as expected for a nonglycosylated pro-
tein (Fig. 6A).
Ligand blots of total H. ducreyi proteins (strain 35000HP)
probed with glycosidase-treated glycoproteins are shown in
Fig. 6B. Glycosidase treatment dramatically reduced the bind-
ing of DIG-FN, DIG-fH, and DIG-Tf to DltA compared to
nontreated probes (Fig. 6B). DIG-BSA binding to DltA was
minimally affected after treatment, since DIG-BSA bound very
poorly to DltA prior to treatment (Fig. 6B). However, DIG-
BSA did bind well to the very abundant protein DsrA, the
protein in the 30-kDa range in Fig. 6B. Although glycosidase
treatment did not affect the binding of DIG-BSA to DsrA, it
did increase the binding of DIG-FN, DIG-fH, and DIG-Tf to
this protein (Fig. 6B). We conclude that glycosidase treatment
affected the mobility of glycoproteins by removing CHO. Fur-
thermore, deglycosylation substantially reduced binding to
DltA. These data suggest that DltA is a lectin that binds lac-
tose-related residues.
Localization of DltA. DltA appeared to be localized in the
OM since it was initially isolated from an OMP preparation.
Fractionation of bacterial membrane proteins can be achieved
with certain detergents (18). With this technique, the more
detergent-soluble inner membrane proteins generally partition
to the Sarkosyl-soluble (SS) fraction, whereas most integral
OMPs fractionate in the SI pellet. To examine the OM local-
ization of DltA, cell fractionation was done. DltA fractionated
with the cell envelope (Fig. 7A, TM in panel 1) and was found
primarily in the SS fraction (Fig. 7A, SS in panel 1). Hlp,
another H. ducreyi lipoprotein previously shown to be surface
exposed (26), fractionated similarly to DltA (Fig. 7A, panel 2).
As another control, we examined the fractionation of the
MOMP, an integral OMP (66). MOMP was found predomi-
nantly in the SI fraction (Fig. 7A, panel 3). Although these data
do not show conclusively that DltA is present in the OM, they
clearly show that it is present in the cell envelope. Further-
more, these data do not exclude the possibility that DltA is sur-
face exposed since Hlp, a known surface-exposed lipoprotein,
also partially fractionated in the SS fraction (Fig. 7A, panel 2).
To determine whether DltA is surface exposed, whole cells
of H. ducreyi were treated with trypsin and chymotrypsin (Fig.
7B). Although we were unable to detect degradation products
of DltA after this treatment (Fig. 7B4), both DsrA and Hlp
were also minimally affected by this procedure, whereas HgbA
was readily cleaved (Fig. 7B7).
Surface exposure of a protein can also be shown by gentle
iodination of intact cells, whereby only surface-exposed OMPs
such as MOMP, OMPA2, DsrA, and HgbA are iodinated (13,
14). When this was performed in wild-type and in dltA dsrA
single and double mutants of H. ducreyi, dltA-expressing strains
showed a more intense band at 22-kDa compared to dltA
mutants (Fig. 8). Intracellular contamination with 125I was
minimal since GroEL, the major H. ducreyi protein in a cyto-
plasmic location (6, 47, 48), was not labeled. These iodination
data suggest that DltA is surface exposed, although more ex-
periments are needed.
The anti-rDltA antiserum was used in whole-cell binding
assays to determine the surface exposure of DltA. However, in
two experiments, there was no difference in binding between
the wild type and the mutants (data not shown). These data
suggest either that this antibody does not bind conformational
epitopes, that the immunodominant epitopes are not exposed,
or that DltA is not surface exposed. Consistent with the notion
that the anti-rDltA antibody binds linear epitopes, it bound to
DltA much better under reducing conditions in Western blot
(Fig. 1B4). Thus, the lack of surface binding by anti-rDltA does
not rule out that DltA is surface exposed.
Serum susceptibility of the dltA mutants. We tested H. du-
creyi strains for sensitivity to NHS. FX533, the single dltA mu-
tant, was significantly more susceptible to 50% NHS (23% sur-
vival) than the parent strain 35000HP (98% survival) (P  0.001)
FIG. 7. Cell fractionation and protease cleavage of H. ducreyi. (A)
Cell fractionation. Whole cells of H. ducreyi strain 35000HP were sub-
jected to detergent fractionation as described in the Materials and Meth-
ods. Then, 10 g of each preparation was subjected to SDS-PAGE and
Western blotting with anti-rDltA, anti-Hlp, and 2C7 antibodies as pri-
mary probes and with anti-rabbit-AP or anti-mouse-AP (2C7) as secon-
dary probes. The blots were developed by using chemiluminescence.
Lanes: SM, starting material; S-100, supernatant from a centrifugation
at 100,000  g; TM, total membranes; SS, SS supernatant; SI, SI pellet.
(B) Protease cleavage. H. ducreyi cells from strains FX517 and FX533
(ca. 2  108 CFU/ml) were subjected to protease cleavage with either
chymotrypsin (5 g/ml) or trypsin (20 g/ml) for 2 min at 35°C. Cells were
pelleted, solubilized in Laemmli sample buffer, and subjected to SDS-
PAGE (107 CFU/lane) in reducing conditions and Western blotting.
Lanes: 0, before protease treatment; 2, after 2 min of protease treatment.
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(n  6) (Fig. 9A). The serum resistance of FX533 was partially
restored when dltA was expressed from pUNCH1286 (84%
survival; P  0.205) but not with the vector pLSKS alone (21%
survival [P  0.0001 compared to 35000HP]). In 50% NHS,
strain FX534dltAdsrA was as susceptible as strain FX517dsrA
(0% survival; Fig. 9A). However, in 10% NHS (Fig. 9B), the
double mutant was significantly more susceptible (35% sur-
vival) than the dsrA single mutant strain (69% survival) (n 
10) (P  0.012).
When dltA was expressed in H. influenzae strain Rd from
pUNCH1286, it rendered this highly susceptible strain partially
resistant to 5% NHS (51% survival) compared to the parent
strain (10% survival) (n  3) (P  0.01). These data indicate
that DltA is required for expression of a full serum resistance
phenotype in H. ducreyi.
DltA expression and conservation. We first examined the
expression of DltA at different stages of growth in broth and
found that there were no obvious differences in the amount of
the DltA expressed (data not shown). DltA expression was also
examined in a variety of temporally and geographically diverse
strains (38 strains were tested). All strains studied expressed a
22-kDa protein that reacted with the polyclonal anti-rDltA
generated from strain 35000HP (data not shown).
DISCUSSION
We provide here functional and structural evidence that
DltA from H. ducreyi is a lectin. Functionally, we showed two
lines of evidence that DltA binds CHO. First, we were able to
affinity purify native DltA from Zwittergent-soluble total cel-
lular protein from H. ducreyi by using immobilized lactose and
GalNAc. Second, glycosidase treatment of glycoproteins re-
duced their binding to DltA in ligand blots. We also provided
structural evidence that DltA is a lectin by showing that it has
homology to the  chain of ricin. Both proteins contain QxW
lectin repeats at the primary amino acid level, a common
hallmark of R-type lectins of similarity (23). Furthermore, the
number and position of cysteines are also conserved. Cysteines
FIG. 8. Cell surface iodination of whole H. ducreyi cells. Whole
cells of H. ducreyi (ca. 5  108 CFU) were surface labeled with 125I and
subjected to SDS-PAGE in reducing conditions. The gel was stained
with Coomassie blue stain, destained, and dried. The left panel of the
figure shows the Coomassie blue-stained gel, and the right panel shows
the autoradiograph.
FIG. 9. Serum susceptibility of single dltA and double dltA dsrA H.
ducreyi mutants in 50% NHS (A) and 10% NHS (B) and the serum
susceptibility of H. influenzae strain Rd expressing dltA in 5% NHS
(C). Strains were mixed with either heated NHS (NHS) or fresh
(fNHS) for 45 min at 35°C, and viable counts were determined by
plating. The data are expressed as percent survival in fNHS compared
to survival in NHS [i.e., (the number of CFU in fNHS/the number of
CFU in NHS)  100]. The data are compiled from separate exper-
iments performed on at least three different days. The asterisk denotes
statistically different survival rates between the indicated strain and the
parent strain (35000HP for panels A and B and H. influenzae strain Rd
complemented with pLSKS for panel C). The double asterisk denotes
statistically different survival rates between FX534 and FX517 (in
panel B).
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are important in ricin to form the , , and  secondary
structure domains and for binding CHO (23). Thus, we con-
clude that DltA is a lectin.
The ricin  chain has two lectin domains each capable of
binding a lactose molecule (45, 59). DltA has a single lectin
domain, and it is most similar to the first domain of ricin. Each
ricin domain can be divided in three subdomains (, , and ),
each containing a QxW internal lectin repeat (23). We identi-
fied three subdomains in DltA (Fig. 2), although in two of the
three QxW repeats, the “W” was conservatively replaced with
an “F.” This substitution has also been found in BoNT hem-
agglutinin domains 1 and 2, mosquitocidal toxin domains 1 and
2 and in bovine GalNAc transferase (23).
Protein sequence comparison also revealed that the cys-
teines from the ricin  chain are conserved in DltA (Fig. 2).
Cysteines in the ricin  chain and in many QxW repeat pro-
teins form conserved disulfide bonds and are functionally im-
portant (23). By analogy to other R-type lectins that have been
more intensively studied (23, 59), we speculate that cysteines 2
and 3, cysteines 4 and 5, and cysteines 6 and 7 are involved in
intrapeptide disulfide bonds in DltA. Intrapeptide bonds were
critical to the function of DltA because the addition of a
reducing agent (ME) for a ligand blot significantly reduced
DIG-FN binding to DltA (Fig. 1B). The presence of three
disulfide bonds in such a small protein also suggests that DltA
exhibits a small compact structure. We predict that the C-
terminal two-thirds of DltA containing the lectin module is
exposed to the external face of the OM, and the lipid tail,
affixed to the N-terminal one-third, is associated with the OM.
In the present study, we conclude that DltA is a lectin be-
cause it binds to lactose and GalNAc in affinity chromatogra-
phy experiments (Fig. 5) and to several N-glycosylated glyco-
proteins in ligand blots (Fig. 6). Lectins from many pathogenic
organisms have been shown to be important adhesion mole-
cules involved in the initiation of infection (62). In the case of
chancroid, H. ducreyi is thought to enter the skin through
microabrasions (65). However, very little is known about how
H. ducreyi binds to cells and the ECM to cause disease. In the
human model of chancroid, H. ducreyi has been shown to
associate with fibrin, collagen, macrophages, and polymorpho-
nuclear leukocytes (3, 65). Since these ECM proteins and eu-
karyotic cells are glycosylated, DltA may play a role in adhe-
sion of H. ducreyi to components of the skin and initiation of
infection. Future studies to determine the role of DltA in the
pathogenesis of chancroid include testing the dltA mutant in
the pig and human models of chancroid and studying the
binding phenotype of this mutant in cell culture.
Several lines of evidence suggest that DltA is localized to the
OM. First, DltA was originally purified and sequenced from a
SI OMP preparation. Second, most serum-susceptible mutants
are the result of mutation in a gene encoding OM constituents,
including the previously described DsrA and MOMP of H.
ducreyi (16, 25). Third, the sequence of DltA predicts its export
to the OM. Indeed, type II signal sequences contain the con-
sensus sequence LXXC (termed a lipobox), where C is the first
amino acid of the mature protein and is acylated (35). The




lipobox affords a protein containing this sequence lipid modi-
fication and localization to the membrane (46). However, it is
the amino acid in position “2” (X2), the amino acid imme-
diately after the acylated cysteine “C1” contained in the li-
pobox that determines whether the protein is inserted in the
cytoplasmic membrane or the OM (61). An aspartate residue
in “X2” position predicts retention of the protein in the cy-
toplasmic membrane, whereas any other amino acid in this
position sends the protein to the OM (61). DltA possesses a
valine residue at position “X2” (Fig. 2), suggesting that it is
translocated to the OM. This is also true of two other H. du-
creyi lipoproteins, Hlp and PAL. Hlp has an aspartic acid (26)
at position “X2” and PAL, a serine (64), which is consistent
with the notion of surface exposure, at least for Hlp (26).
Finally, the other data that suggest that DltA may be present at
the surface of the cell comes from iodination experiments
shown in the present study. Indeed, we demonstrate that dltA-
expressing strains show a more intense signal in the 22-kDa
range after surface labeling compared to dltA mutants (Fig. 8).
Overall, these data are consistent with the presence of DltA in
the OM and suggest that DltA is surface exposed.
Some data imply that DltA may not be surface accessible.
FN and fH that bound to DltA in a ligand blot did not bind
DltA expressed in the membrane of whole H. ducreyi cells
(data not shown). Although the glycoproteins used here bind
DltA in a ligand blot, there is no evidence that they are the
natural ligands. In addition, trypsin and chymotrypsin treat-
ment of intact H. ducreyi cells did not result in DltA cleavage.
Conceivably, the small compact structure proposed for DltA
may account for the lack of surface accessibility. Conversely,
DltA may be resistant to protease cleavage, which may to be
the case for DsrA and Hlp (Fig. 7B). More experiments are
needed to prove that DltA is surface exposed.
Some bacterial heme acquisition systems, such as in Neisse-
ria spp., contain lipoproteins as part of the receptor complex
required for hemoglobin utilization (60). Apparently, DltA
does not function as part of the hemoglobin utilization system
of H. ducreyi since the dltA mutant (FX533) grew as well as the
parent strain 35000HP on medium containing hemoglobin as
the sole source of heme (data not shown).
An H. ducreyi dltA mutant exhibited a moderate degree of
serum susceptibility. However, the profound susceptibility of
the double dltA dsrA mutant indicates that these mutations are
additive, if not synergistic. The finding of a second locus, dltA,
important for the expression of serum resistance is not surpris-
ing, given the redundant nature of many bacterial systems for
essential properties such as iron acquisition (60) and serum
resistance (54, 57). In earlier studies, we found that DsrA was
an important determinant for expression of serum resistance.
Along with the previously described momp (ompA1) locus (25),
this brings to three the number of loci important for expression
of complete serum resistance phenotype in H. ducreyi.
The H. ducreyi genome is relatively small (28) (www.ncbi
.nlm.nih.gov/genomes/chrom.cgi?gi  309&db  G and http:
//www.stdgen.lanl.gov/), and one way of utilizing this limited
genetic information is to evolve or acquire proteins with mul-
tiple functions. DsrA is multifunctional in that it mediates
serum resistance (16) and attachment to keratinocytes and
vitronectin (8) and is required for virulence in the experimen-
tal model of human chancroid infection (4). We do not know
the natural ligands for DltA, but it is possible there are several,
given the widespread nature of glycosylation. In ligand blots,
where the surrounding membrane and other OMPs do not
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shield DltA, it binds a number of glycoproteins. The relative
inaccessibility of DltA in the context of intact cells may confer
specificity for its natural ligand(s). DltA may also influence
serum susceptibility by interfering with the complement cas-
cade, perhaps by binding a negative regulator of C. An alter-
native or additional function is suggested by the similarity of
DltA to the ricin  chain; DltA may mediate binding to host
cell membrane glycoproteins. Studies are now under way to
answer these important questions.
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